Follow-up study of "Evaluation for new Phosphate Iron-based binder, Sucroferric Oxyhydroxide in Dialysis patient for E.B.M (EPISODE)"

Follow-up study of "Evaluation for new Phosphate Iron-based binder , Sucroferric Oxyhydroxide in Dialysis patient for E.B.M (EPISODE)" - Follow-up study of EPISODE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043661

Enrollment

156

Registered

2021-05-01

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperphosphatemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients enrolled in the EPISODE trial and receiving the allocation drugs 2. Patients who can be followed up 3. Patients given written informed consent. (opt-out is also available)

Exclusion criteria

Exclusion criteria: Research investigators or research sharing investigators have determined to the patient is inappropriate as a subject of the study.

Design outcomes

Primary

Measure	Time frame
Onset of CVD events between factors (drug group, treatment group) after completion of EPISODE study	—

Secondary

Measure	Time frame
Fluctuations in laboratory test values between factors (drug group, treatment group) after completion of EPISODE study	—

Countries

Japan

Contacts

Public ContactKiyomi Kanda

The Japan Clinical Research Forum Secretariat

e-extension@jarf.or.jp06-6398-5192

Outcome results